

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12N 15/86, 15/45, C07K 14/135, 14/115, A61K 31/70</p>		<p>A1</p>	<p>(11) International Publication Number: WO 99/25858</p> <p>(43) International Publication Date: 27 May 1999 (27.05.99)</p>
<p>(21) International Application Number: PCT/CA98/01064</p> <p>(22) International Filing Date: 13 November 1998 (13.11.98)</p> <p>(30) Priority Data: 60/065,791 14 November 1997 (14.11.97) US</p> <p>(71) Applicant (for all designated States except US): CONNAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Avenue West, North York, Ontario M2R 3T4 (CA).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): PARRINGTON, Mark [CA/CA]; 45 Martin Street, Bradford, Ontario L3Z 1Z4 (CA). LI, Xiaomao [CN/CA]; 106 Glenmanor Way, Thornhill, Ontario L4J 3E5 (CA).</p> <p>(74) Agent: STEWART, Michael, I.; 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: ALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES</p> <p>(57) Abstract</p> <p>A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter, preferably a cytomegalovirus promoter, which may include Intron A. Such vectors also contain a further nucleotide sequence located between the promoter sequence and the alphavirus sequence to enhance the immunoprotective ability of the RSV F protein when expressed <i>in vivo</i>. Such DNA vectors may be used to immunize a host against disease caused by infection with RSV or other paramyxovirus, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purposes. Such vectors also may be used to produce antibodies for detection of RSV or other paramyxovirus infection in a sample.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF INVENTIONALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES

5

FIELD OF INVENTION

The present invention relates to the field of paramyxoviridae vaccines and is particularly concerned with vaccines comprising DNA encoding the fusion (F) protein of respiratory syncytial virus (RSV) in an
10 alphavirus vector.

BACKGROUND OF THE INVENTION

Human respiratory syncytial virus (RSV) has been identified as a major pathogen responsible for severe
15 respiratory tract infections in infants, young children and the institutionalized elderly (refs. 1,2,3,4 - throughout this application, various references are cited in parentheses to describe more fully the state of the art to which this invention pertains. Full
20 bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby incorporated by reference into the present disclosure). Global mortality and morbidity figures indicate that
25 there is an urgent need for an efficacious RSV vaccine (refs. 5,6). In the USA alone, approximately 100,000 children are hospitalized annually with severe cases of pneumonia and bronchiolitis resulting from an RSV infection. Inpatient and ambulatory care for children
30 with RSV infections has been estimated to cost in excess of \$340 million each year in the USA. The World Health Organization (WHO) and the National Institute of Allergy and Infectious Disease (NIAID) vaccine advisory

committees have ranked RSV second only to HIV for vaccine development. Both the annual morbidity and mortality figures as well as the staggering health care costs for managing RSV infections have provided the
5 incentive for aggressively pursuing the development of efficacious RSV vaccines. However, such a vaccine is still not available.

Formalin-inactivated (FI-RSV) and live attenuated RSV vaccines have failed to demonstrate efficacy in
10 clinical trials (refs. 7,8,9,10). Moreover, the formalin-inactivated RSV vaccine caused enhanced disease in some children following exposure to wild-type RSV (refs. 7,8,9,10). Elucidation of the mechanism(s) involved in the potentiation of RSV disease is important
15 for the design of safe RSV vaccines, especially for the seronegative population. Recent experimental evidence suggests that an imbalance in cell-mediated responses may contribute to immunopotential. Enhanced histopathology observed in mice that were immunized with
20 the FI-RSV and challenged with virus could be abrogated by depletion of CD4+ cells or both interleukin-4 (IL-4) and IL-10.

The RSV fusion (F) glycoprotein is one of the major immunogenic proteins of the virus. This envelope
25 glycoprotein mediates both fusion of the virus to the host cell membrane and cell-to-cell spread of the virus (ref. 1). The F protein is synthesized as a precursor (F₀) molecule which is proteolytically cleaved to form a disulphide-linked dimer composed of the N-terminal F₂ and C-terminal F₁ moieties (ref. 11). The amino acid
30 sequence of the F protein is highly conserved among RSV

subgroups A and B and is a cross-protective antigen (refs. 6,12). In the baculovirus expression system, a truncated secreted version of the RSV F protein has been expressed in *Trichoplusia ni* insect cells (ref. 13). The recombina⁵nt protein was demonstrated to be protective in the cotton rats (ref. 13).

Studies on the development of live viral vaccines and glycoprotein subunit vaccines against parainfluenza virus infection are being pursued. Clinical trial results with a formalin-inactivated PIV types 1,2,3 vaccine demonstrated that this vaccine was not efficacious (refs. 14, 15, 16). Further development of chemically-inactivated vaccines was discontinued after clinical trials with a formalin-inactivated RSV vaccine demonstrated that not only was the vaccine not effective in preventing RSV infection but many of the vaccinees who later become infected with RSV suffered a more serious disease. Most of parainfluenza vaccine research has focused on candidate PIV-3 vaccines (ref. 17) with significantly less work being reported for PIV-1 and PIV-2. Recent approaches to PIV-3 vaccines have included the use of the closely related bovine parainfluenza virus type 3 and the generation of attenuated viruses by cold-adaptation of the virus (refs. 18, 19, 20, 21).

Another approach to parainfluenza virus type 3 vaccine development is a subunit approach focusing on the surface glycoproteins hemagglutinin-neuraminidase (HN) and the fusion (F) protein (refs. 22, 23, 24). The HN antigen, a typical type II glycoprotein, exhibits both haemagglutination and neuraminidase activities and

is responsible for the attachment of the virus to sialic acid containing host cell receptors. The type I F glycoprotein mediates fusion of the viral envelope with the cell membrane as well as cell to cell spread of the virus. It has recently been demonstrated that both the HN and F glycoproteins are required for membrane fusion. The F glycoprotein is synthesized as an inactive precursor (F) which is proteolytically cleaved into disulfide-linked F2 and F1 moieties. While the HN and F proteins of PIV-1, -2 and -3 are structurally similar, they are antigenically distinct. Neutralizing antibodies against the HN and F proteins of one of PIV type are not cross-protective. Thus, an effective PIV subunit vaccine must contain the HN and F glycoproteins from the three different types of parainfluenza viruses. Antibody to either glycoprotein is neutralizing in vitro. A direct correlation has been observed between the level of neutralizing antibody titres and resistance to PIV-3 infections in infants. Native subunit vaccines for parainfluenza virus type 3 have investigated the protectiveness of the two surface glycoproteins. Typically, the glycoproteins are extracted from virus using non-ionic detergents and further purified using lectin affinity or immunoaffinity chromatographic methods. However, neither of these techniques may be entirely suitable for large scale production of vaccines under all circumstances. In small animal protection models (hamsters and cotton rats), immunization with the glycoproteins was demonstrated to prevent infection with live PIV-3 (refs. 25, 26, 27, 28, 29).

The HN and F glycoproteins of PIV-3 have also been produced using recombinant DNA technology. HN and F glycoproteins have been produced in insect cells using the baculovirus expression system and by use of vaccinia virus and adenovirus recombinants (refs. 30, 31, 32, 33, 34). In the baculovirus expression system, both full-length and truncated forms of the PIV-3 glycoproteins as well as a chimeric F-HN fusion protein have been expressed. The recombinant proteins have been demonstrated to be protective in small animal models (see WO91/00104, US Application No. 07/773,949 filed November 29, 1991, assigned to the assignee hereof).

Semliki Forest virus (SFV) is a member of the Alphavirus genus in the Togaviridae family. The mature virus particle contains a single copy of a ssRNA genome with a positive polarity that is 5'-capped and 3'-polyadenylated. It functions as an mRNA and naked RNA can start an infection when introduced into cells. Upon infection/transfection, the 5' two-thirds of the genome is translated into a polyprotein that is processed into the four nonstructural proteins (nsP1 to 4) by self cleavage. Once the ns proteins have been synthesized they are responsible for replicating the plus-strand (42S) genome into full-length minus strands (ref. 14). These minus-strands then serve as templates for the synthesis of new plus-strand (42S) genomes and the 26S subgenomic mRNA (ref. 14). This subgenomic mRNA, which is colinear with the last one-third of the genome, encodes the SFV structural proteins.

In 1991 Liljestrom and Garoff (ref. 15) designed a series of expression vectors based on the SFV cDNA

replicon. These vectors had the virus structural protein genes deleted to make the way for heterologous inserts, but preserved the nonstructural coding region for production of the nsP1 to 4 replicase complex.

5 Short 5' and 3' sequence elements required for RNA replication were also preserved. A polylinker site was inserted downstream from the 26S promoter followed by translation stop sites in all three frames. An SpeI site was inserted just after the 3' end of the SFV cDNA
10 for linearization of the plasmid for use in vitro transcription reactions.

Injection of SFV RNA encoding a heterologous protein have been shown to result in the expression of the foreign protein and the induction of antibody in a
15 number of studies (refs. 16,17). The use of SFV RNA inoculation to express foreign proteins for the purpose of immunization would have several of the advantages associated with plasmid DNA immunization. For example, SFV RNA encoding a viral antigen may be introduced in
20 the presence of antibody to that virus without a loss in potency due to neutralization by antibodies to the virus. Also, because the protein is expressed in vivo the protein should have the same conformation as the protein expressed by the virus itself. Therefore,
25 concerns about conformational changes which could occur during protein purification leading to a loss in immunogenicity, protective epitopes and possibly immunopotential, could be avoided by plasmid DNA immunization.

30 In copending US Patent Application No. 08/476,397 filed June 7, 1995, assigned to the assignee hereof and

the disclosure of which is incorporated herein by reference (WO96/040945), there is described reference the use of plasmid vectors containing RSV F protein-encoding DNA for DNA immunization against RSV infection.

5 In copending United States Patent Application No. 08/896,500 filed July 18, 1997, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference, there is described the use of plasmid vectors containing RSV G protein-encoding DNA

10 for DNA immunization against RSV infection.

In my copending United States Patent Application No. 08/923,558, filed September 4, 1997, assigned to the assignee hereof and the disclosure of which is incorporated by reference, I describe a DNA vector using

15 an alphavirus vector, including Semliki Forest virus vector, containing a DNA sequence encoding a paramyxovirus protein, specifically RSV-F, for making an RNA transcript for immunization.

In WO95/27044, the disclosure of which is incorporated herein by reference, there is described the use of alphavirus cDNA vectors based on cDNA complementary to the alphavirus RNA sequence. Once transcribed from the cDNA under transcriptional control of a heterologous promoter, the alphavirus RNA is able

25 to self-replicate by means of its own replicase and thereby amplify the copy number of the transcribed recombinant RNA molecules.

Infection with RSV leads to serious disease. It would be useful and desirable to provide improved

30 vectors for *in vivo* administration of immunogenic preparations, including vaccines, for protection against

disease caused by RSV and other paramyxoviruses. In particular, it would be desirable to provide vaccines that are immunogenic and protective in humans, including seronegative infants, that do not cause disease enhancement (immunopotentiality).

SUMMARY OF THE INVENTION

The present invention provides novel immunogenic materials and immunization procedures based on such novel materials for immunizing against disease caused by respiratory syncytial virus. In particular, the present invention is directed towards the provision of DNA vaccines against disease caused by infection with paramyxoviridae.

In accordance with one aspect of the present invention, there is provided a vector, comprising a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; a second DNA sequence encoding a paramyxovirus protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication; the first and second DNA sequences being under transcriptional control of a promoter; and a third DNA sequence located adjacent the second DNA sequence to enhance the immunoprotective ability of the paramyxovirus protein when expressed *in vivo* from the vector in a host.

The paramyxovirus protein may be selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial virus (RSV). The PIV protein may be from PIV-1, PIV-2, PIV-3 or PIV-4, particularly the
5 HN and F glycoproteins of PIV-3. The RSV protein particularly may be the F or G glycoprotein of RSV.

The second DNA sequence may encode a full length RSV F protein, or may encode a RSV F protein lacking the transmembrane anchor and cytoplasmic tail. The
10 lack of the coding region for the transmembrane anchor and cytoplasmic tail results in a secreted form of the RSV F protein. Alternatively, as described in the aforementioned U.S. Patent Application 08/896,500, the second DNA sequence may encode the full-length RSV-G
15 protein or a truncated RSV G protein lacking a transmembrane region, resulting in a secreted form of the protein.

The alphavirus preferably is a Semliki Forest virus and the first DNA sequence is the Semliki Forest viral
20 sequence contained in plasmid pSFVI.

The third nucleotide sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing, *in vivo*, whereby substantially all transcribed mRNA from the vector upon administration encodes the RSV protein.
25 Such third nucleotide sequence is preferably located between the first nucleotide sequence and the promoter sequence. Such third nucleotide sequence may be that of rabbit β -globin intron II, as shown in Figure 8 of copending U.S. Patent Application No. 08/476,397 (WO
30 96/040945).

10

The promoter sequence may be an immediate early cytomegalovirus (CMV) promoter. The human cytomegalovirus Intron A sequence may be provided downstream of the promoter and upstream of the third
5 nucleotide sequence.

A vector encoding the F protein and provided in accordance with one embodiment of the invention may be specifically pMP44, having the identifying characteristics shown in Figure 1D.

10 The vectors provided herein may be used to immunize a host against RSV infection or disease by *in vivo* expression of RSV F protein or RSV G protein, which may lack a transmembrane region, or other paramyxovirus protein, following administration of the vectors. In
15 accordance with a further aspect of the present invention, therefore, there is provided a method of immunizing a host against disease caused by infection with respiratory syncytial virus or other paramyxovirus, which comprises administering to the host an effective
20 amount of a vector provided herein.

The present invention also includes a novel method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of generating antibodies which specifically react with RSV F or G
25 protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises isolating the gene; operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the
30 complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-

essential for replication to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; operatively linking the gene to an immunoprotection enhancing sequence to produce an enhanced immunoprotection by the RSV F or G protein in the host, preferably by introducing the immunoprotection enhancing sequence between the control sequence and the alphavirus sequence; and introducing the vector into the host. A corresponding procedure may be used for other paramyxoviridae.

In addition, the present invention includes a method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent; operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; operatively linking the first nucleotide sequence to a third nucleotide sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* from the vector in a host; and formulating the vector as a vaccine for *in vivo* administration. A corresponding procedure may be used for other paramyxoviridae.

The present invention further includes a vaccine for administration to a host, including a human host, produced by the method as well as immunogenic compositions comprising an immunoeffective amount of the
5 vectors described herein.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1A to 1B show a schematic of a procedure of assembly of vector pMP44;

Figures 2A to 2B show a schematic of a procedure of
10 assembly of vector pMP44;

Figures 3A to 3E contain the nucleotide sequence of plasmid pMP44 (SEQ ID NO:1);

Figure 4 shows the anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after
15 boosting;

Figure 5 shows the nucleotide sequence for a synthetic oligonucleotide coding for the hepatitis delta ribozyme (SEQ ID no; 2,3); and

Figures 6A to 6C show the nucleotide sequence for
20 the SFV EcoRV-SpeI fragment ligated to the ribozyme of Figure 5 (SEQ ID no: 4).

GENERAL DESCRIPTION OF INVENTION

As described above, the present invention, in general, relates to protection of hosts against disease caused by infection by paramyxovirus by DNA immunization using DNA vectors. In particular, the invention is concerned with protection of hosts against disease caused by infection by respiratory syncytial virus (RSV), although not specifically limited thereto. The description which follows refers specifically to employing DNA sequences encoding RSV F or G protein and fragments thereof which generate antibodies which specifically react with RSV F or G protein.

In this application, the terms "RSV F protein" and "RSV G protein" are used to define a full-length RSV F or G protein, including proteins having variations in their amino acid sequences including those naturally occurring in various strain of RSV and those introduced by PCR amplification of the encoding gene while retaining the immunogenic properties, a secreted form of the RSV F or G protein lacking a transmembrane anchor and cytoplasmic tail, as well as fragments capable of generating antibodies which specifically react with RSV F or G protein and functional analogs. In this application, a first protein is a "functional analog" of a second protein if the first protein is immunologically related to and/or has the same function as the second protein. The functional analog may be, for example, a fragment of the protein or a substitution, addition or deletion mutant thereof.

A vector is constructed to contain a first DNA sequence which is complementary to at least part of an

alphavirus RNA genome, specifically Semliki Forest virus, and having the complement of complete alphavirus RNA genome replication regions to permit replication *in vivo*. A second DNA sequence encoding the RSV F or G protein is inserted into a region of the first DNA sequence which is non-essential for replication. The first and second DNA sequences are under transcriptional control of a promoter to permit expression of the RSV protein in a host immunized with the vector.

10 The promoter sequence may be the immediately early cytomegalovirus (CMV) promoter. This promoter is described in ref. 36. Any other convenient promoter may be used, including constitutive promoters, such as, Rous Sarcoma Virus LTRs, and inducible promoters, such as
15 metallothionine promoter, and tissue specific promoters.

The recombinant vector may include a third nucleotide sequence located adjacent the alphavirus sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* in a host.
20 Such enhancement may be provided by increased *in vivo* expression, for example, by increased mRNA stability, enhanced transcription and/or translation. This additional sequence preferably is located between the promoter sequence and the alphavirus sequence.

25 This enhancement sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing during transcription so that substantially all transcribed mRNA is intact alphavirus RNA encoding a gene of interest, for example, an RSV F protein. Specifically, rabbit β -globin Intron II sequence may provide such splice sites,
30 as also described in ref. 37.

15

Additional enhancement may be obtained by, including an additional DNA sequence between the promoter and the enhancer sequence. Such additional DNA sequence may comprise the immediate early
5 cytomegalovirus Intron A sequence.

The vectors provided herein, when administered to an animal, effect *in vivo* RSV F protein expression, as demonstrated by an antibody response in the animal to which it is administered and the conferring of
10 protection. As may be seen from the results detailed in the Examples below, the DNA vectors produced a high anti-F IgG antibody titre and confer protection.

In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/476,397
15 and 08/896,500, the vectors described herein provide a protective immune response using a lower dose and less time. In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/923,558, 08/896,550 and 08/476,397 using native RSV F, the
20 vectors described herein produce protective immune response in the absence of pretreatment of the animal model with cardiotoxin, a material known to increase the uptake of DNA and enhance the immune response.

The vector provided herein may also comprise a
25 fourth nucleotide sequence encoding a further antigen from RSV, an antigen from at least one other pathogen or at least one immunomodulating agent, such as cytokine. Such vector may contain said fourth nucleotide sequence in a chimeric or a bicistronic structure. Alternatively,
30 vectors containing the fourth nucleotide sequence may be

separately constructed and coadministered to a host, with the DNA vector provided herein.

In addition, there may be provided at the 3'-end of the Simliki Forest virus segment, a hepatitis delta virus ribosyme sequence to ensure proper *in vivo* cleavage at the 3'-end of the Simliki Forest virus sequence. Any other convenient sequence may be employed to achieve this effect.

It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis and treatment of RSV infections. A further non-limiting discussion of such uses is further presented below.

1. Vaccine Preparation and Use

Immunogenic compositions, suitable to be used as vaccines, may be prepared from the RSV F or RSV G genes and other paramyxovirus genes and vectors as disclosed herein. The vaccine elicits an immune response in a subject which includes the production of anti-F or anti-G antibodies. Immunogenic compositions, including vaccines, containing the DNA vector may be prepared as injectables, in physiologically-acceptable liquid solutions or emulsions for polynucleotide administration. The nucleic acid may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a nucleic acid liposome (for example, as described in WO 93/24640, ref. 38) or the DNA vector may be associated with an adjuvant, as described in more detail below. Liposomes comprising cationic lipids interact spontaneously and rapidly with

polyanions such as DNA and RNA, resulting in liposome/nucleic acid complexes that capture up to 100% of the polynucleotide. In addition, the polycationic complexes fuse with cell membranes, resulting in an intracellular delivery of polynucleotide that bypasses the degradative enzymes of the lysosomal compartment. Published PCT application WO 94/27435 describes compositions for genetic immunization comprising cationic lipids and polynucleotides. Agents which assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins and other transfection facilitating agents, may advantageously be used.

Polynucleotide immunogenic preparations may also be formulated as microcapsules, including biodegradable time-release particles. Thus, U.S. Patent 5,151,264 describes a particulate carrier of a phospholipid/glycolipid/polysaccharide nature that has been termed Bio Vecteurs Supra Moléculaires (BVSM). The particulate carriers are intended to transport a variety of molecules having biological activity in one of the layers thereof.

U.S. Patent 5,075,109 describes encapsulation of the antigens trinitrophenylated keyhole limpet hemocyanin and staphylococcal enterotoxin B in 50:50 poly (DL-lactide-co-glycolide). Other polymers for encapsulation are suggested, such as poly(glycolide), poly(DL-lactide-co-glycolide), copolyoxalates, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramides), polyorthoesters and poly(8-hydroxybutyric acid), and polyanhydrides.

Published PCT application WO 91/06282 describes a delivery vehicle comprising a plurality of bioadhesive microspheres and antigens. The microspheres being of starch, gelatin, dextran, collagen or albumin. This
5 delivery vehicle is particularly intended for the uptake of vaccine across the nasal mucosa. The delivery vehicle may additionally contain an absorption enhancer.

The RSV F or G genes and vectors may be mixed with pharmaceutically acceptable excipients which are
10 compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents,
15 or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intravenously, intradermally or intramuscularly, possibly following pretreatment of the injection site
20 with a local anaesthetic. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to
25 mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example,
30 polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients,

such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate.

The immunogenic preparations and vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize the RSV F protein and antibodies thereto, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of about 1 μ g to about 1 mg of the RSV F or G genes and vectors. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage may also depend on the route of administration and will vary according to the size of the host. A vaccine which protects against only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

In particular embodiments of the present invention, the vector comprising a first nucleotide sequence

encoding an F or G protein of RSV may be delivered in conjunction with a targeting molecule to target the vector to selected cells including cells of the immune system.

5 The DNA vectors may be delivered to the host by a variety of procedures, for example, Tang et al. (ref. 39) disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH
10 antibodies in the mice, while Furth et al. (ref. 40) showed that a jet injector could be used to transfect skin, muscle, fat and mammary tissues of living animals.

2. Immunoassays

 The RSV F or G genes and vectors of the present
15 invention are useful as immunogens for the generation of anti-F or anti-G antibodies for use in immunoassays, including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or procedures known in the art. In ELISA assays, the
20 vector first is administered to a host to generate antibodies specific to the RSV F or G protein or other paramyxovirus protein. These RSV F- or G-specific antibodies are immobilized onto a selected surface, for example, a surface capable of binding the antibodies,
25 such as the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed antibodies, a nonspecific protein such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample may
30 be bound to the selected surface. This allows for blocking of nonspecific adsorption sites on the

21

immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.

The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This procedure may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound RSV F specific antibodies, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined.

Biological Deposits

Certain vectors that contain the gene encoding RSV F protein and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, VA 20110-2209, U.S.A., pursuant to the Budapest Treaty and prior to the filing of this application.

Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application and all restrictions on access to the deposits will be removed

22

at that time. Non-viable deposits will be replaced.
The invention described and claimed herein is not to be
limited in scope by plasmids deposited, since the
deposited embodiment is intended only as an illustration
5 of the invention. Any equivalent or similar plasmids
that encode similar or equivalent antigens as described
in this application are within the scope of this
invention.

Deposit Summary

	<u>Plasmid</u>	<u>ATCC Designation</u>	<u>Date Deposited</u>
10	pMP37	97905	Feb. 27, 1997
	pMP42		

EXAMPLES

The above disclosure generally describes the
15 present invention. A more complete understanding can
be obtained by reference to the following specific
Examples. These Examples are described solely for
purposes of illustration and are not intended to limit
the scope of the invention. Changes in form and
20 substitution of equivalents are contemplated as
circumstances may suggest or render expedient. Although
specific terms have been employed herein, such terms
are intended in a descriptive sense and not for
purposes of limitations.

25 Methods of molecular genetics, protein
biochemistry and immunology used but not explicitly
described in this disclosure and these Examples are
amply reported in the scientific literature and are
well within the ability of those skilled in the art.

30

EXAMPLE 1

This Example describes a scheme for construction of a Semliki Forest Virus (SFV) DNA expression vector containing a truncated RSV F gene as outlined in
5 Figures 1A to 1B.

Plasmid VR1012 was restricted with PstI and then made blunt-ended with T4 DNA polymerase. The β -globin Intron II was exised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid
10 pIIE. Plasmid pIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the nucleotide sequence:

```
TCGACATGGCGGATGTGTGACATACACGACGCCAAAAGATTTTGTTCAGCT
CCTGCCACCTCCGCTACGCGAGAGATTAACCACCCACGATGGCCGCCAAAGT
15 GCATGTTGATATTGAGGCTGACAGCCCATTTCATCAAGTCTTTGCAGAAGGCA
TTTCCGTCGTTTCGAGGTGGAGTCATTGCAGGTACACCAAATGACCATGCAA
ATGCCAGAGCATTTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from
pSFVI with primers SAL-SFV having the nucleotide
20 sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:
5) and ECO-SFV having the nucleotide sequence 5'-
TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The
resulting plasmid pMP38 was then restricted with EcoRV
and BamHI and then dephosphorylated. Plasmid pSFV1
25 link (see copending application no. _____ (b/o
1038-766)) was then restricted with SpeI and ligated to
the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and
3). The ligation reaction was then restricted with
EcoRV to release most of the SFV-RSVF plus ribozyme
30 fragment. This fragment was then ligated to
EcoRV/BamH1 restricted pMP38 to produce pMP41.
```

Example 2

This Example describes an alternative scheme for constructing plasmid pMp44 as outlined in Figure 2.

Plasmid VR1012 was restricted with PstI and then
5 made blunt-ended with T4 DNA polymerase. The β -globin
Intron II was excised out of vector pSG5 (Stratagene)
and ligated into plasmid VR1012 to generate plasmid
pIIE. Plasmid pIIE was then restricted with SalI and
EcoRV and ligated to a PCR fragment having the
10 nucleotide sequence:

TCGACATGGCGGATGTGTGACATACACGACGCCAAAAGATTTTGTTCAGCT
CCTGCCACCTCCGCTACGCGAGAGATTAACCACCCACGATGGCCGCCAAAGT
GCATGTTGATATTGAGGCTGACAGCCCATTCATCAAGTCTTTGCAGAAGGCA
TTTCCGTCGTTTCGAGGTGGAGTCATTGCAGGTCACACCAAATGACCATGCAA
15 ATGCCAGAGCATTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from
pSFVI with primers SAL-SFV having the nucleotide
sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:
5) and ECO-SFV having the nucleotide sequence 5'-
20 TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The
resulting plasmid pMP38 was then restricted with EcoRV
and BamHI and then dephosphorylated. Plasmid pSFV1
link (see copending application no. _____ (b/o
1038-766)) was then restricted with SpeI and ligated to
25 the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and
3).

The ligation reaction product was then restricted
with EcoRV to release the SFV replicon plus the
ribozyme having the nucleotide sequence as outlines in
30 Figures 6A to 6C. This fragment was then ligated to
the EcoRV/BamHI restricted pMP38 to produce pMP42. The

25

RSV F gene fragment was released from pMP37 by restriction with BamHI, and this fragment was ligated into the BamHI site of pMP42 to produce pMP44. The nucleotide sequence of pMP44 is shown in Figures 3A to 3E.

EXAMPLE 3

This Example describes the immunization of mice with pMP44 and the immunogenicity results obtained.

BALB/C mice were immunized with plasmid pMP44 by the intramuscular (i.m.) route. The anterior tibialis muscles of six BALB/C mice were bilaterally injected with 2 x 100 μ g of plasmid pMP44. This amount is equivalent to approximately 94 μ g of a conventional vector, based on copy number. These mice were boosted in an identical manner 4 weeks later. The control group was immunized with 2 x 25 μ g of SFV-RSV F RNA as described in my aforementioned United States Application No. 08/923,558, except that the muscles were not pre-treated with cardiotoxin. The immunization protocol is set forth in the following Table I:

Table 1 Immunization protocol

Group	Prime	Route of Inoculation	Boost	Route of Inoculation
25	1 SFV-RSVF RNA ¹	Intramuscular	SFV-RSVF RNA ¹	Intramuscular
	2 pMP44 DNA ²	Intramuscular	pMP44DNA ²	Intramuscular

Mice were inoculated with:

1. 25 μ g of RNA was injected into each hind leg muscle in 50 μ L of PBS
2. 100 μ g of DNA was injected into each hind leg muscle in 50 μ L of PBS

Sera was obtained from the mice at 4 and 6 weeks. Anti-RSV F antibody titres (IgG) in these sera were determined by enzyme-linked immunosorbent assay (ELISA), as described in Example 3.

5 The anti-RSV F IgG antibody response in the sera of the BALB/C mice are summarized in Figure 4. The mice immunized with the DNA construct, pMP44, had higher anti-F titres than the mice immunized with the SFV-RSV F RNA.

10 Two weeks after the second immunization, mice were challenged intranasally with 10^6 plaque forming units (pfu) of the A1 strain of RSV (BG-4A). Animals were sacrificed 4 days later. Lungs were aseptically removed, weighed, and homogenized in 2 mL of complete
15 culture medium. The virus titre in lung homogenates was determined in duplicate using vero cells, as previously described (ref. 41).

As seen in Table 2 below, immunization of mice with pMP44 DNA protected mice (5/6) against live RSV
20 challenge, in contrast to the lack of protection when immunization with SFV-RSV F RNA was effected. This result contrasts with the complete protection which is obtained using SFV-RSV F RNA as described in U.S. Patent Application Nos. 08/923,558, 08/476,397 and
25 08/896,500 where the results show protection after pretreatment with cardiotoxin.

Table 2

Group	Immunogen		Mean Virus Lung Titre	
	Prime	Boost	(log10/g \pm s.d)	% Protection
1	SFV-RSVF RNA	SFV-RSVF RNA	4.26	0
2	pMP44 DNA	pMP44DNA	2.12*	83

* Limit of detection = 1.8

EXAMPLE 4

This Example describes the determination of anti-
5 RSV F antibody titres.

Nunc-MaxiSorp plate wells were coated overnight at room temperature with 2.5 ng of immunoaffinity-purified RSV F protein diluted in 0.05M carbonate-bicarbonate buffer, pH 9.6. Wells were blocked for non-specific
10 binding by adding 0.1% BSA in PBS for 30 min. at room temperature, followed by two washes in a washing buffer of 0.1% BSA in PBS + 0.1% Tween 20. Serial two or four-fold dilutions of mouse serum was added to the wells. After a one hour incubation at room
15 temperature, plates were washed five times with washing buffer, and horseradish peroxidase (HRP) labeled conjugate was added at the appropriate optimal dilution in washing buffer. The total IgG assay used F(ab'), goat antimouse IgG (H+L specific)- HRP from Jackson
20 Immuno Research Laboratory Inc. (Baltimore, MD, USA). Sheep anti-mouse IgG1-HRP from Serotec (Toronto, Ontario, Canada) was used in the IgG1 assay and goat anti-mouse IgG2a from Caltag Laboratories (San Francisco, CA, USA) was used in the IgG2a assay.
25 Following one hour incubation at room temperature, the plates were washed five times with washing buffer, and hydrogen peroxide (substrate) in the presence of tetramethylbenzidine was added. The reaction was stopped by adding 2 M sulfuric acid. The colour was
30 read in a Multiscan Titertek plate reader at an optical density (OD) of 450 nm. The titre was taken as the reciprocal of the last dilution at which the OD was

approximately double. This OD must be greater than the negative control of the assay at the starting dilution. The pre-immune serum of each animal was used as the negative control.

5

SUMMARY OF THE DISCLOSURE

In summary of this disclosure, the present invention provides certain novel alphavirus derived DNA vectors containing genes encoding RSV F or RSV G proteins, or other paramyxovirus proteins, methods of
10 immunization using such vectors and methods of diagnosis using such vectors. Modifications are possible within the scope of this invention.

REFERENCES

1. McIntosh K. and Chanock R.M. in Fields B.N. and Knipe D.M. (eds). Virology. Raven Press, New York, 1990, pp.1045-1072.
2. Murphy B.R., Hall S.L., Kulkarni A.B., Crowe J.E., Collins P.L., Connors M., Karron R.A. and Chanock R.M., Virus Res 32, 13-36, 1994.
3. Osterweil D. and Norman D., Am Geriatr Soc 36, 659-662, 1990.
4. Agius G., Dindinand G., Biggar R.J., Peyre R., Vaillant V., Ranger S., Poupet J.Y., Cisse M.F. and Casters M., J Med Virol 30, 117-127, 1990.
5. Katz S.L. in New vaccine development establishing priorities Vol 1. National Academic Press, Washington, 1985, pp. 3974 09.
6. Wertz G.W. and Sullender W.M., Biotechnology 20, 151-176, 1992 .
7. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M. and Meiklejohn G., Am J Epidemiol 89, 449-463, 1969.
8. Chin J., Magoffin R.L., Shearer I.A., Schieble J.H. and Lennette E.H., Am J Epidemiol 89, 449-463, 1969.
9. Belshe R.B., Van Voris L.P. and Mufson M.A., J Infect Dis 145, 311-319, 1982.
10. Kim R.M., Arrobio J.O., Pyles G., Brandt C.D., Camargo E., Chanock R.M. and Parrott R.H., Pediatrics 48, 745-755, 1971.
11. Gruber C. and Levine S., J Gen Virol 64, 825-832, 1983.
12. Olmstead R.A., Elango N. and Prince G.A., Proc Natl Acad Sci USA 83, 7462-7466, 1991.

13. Parrington M., Cockle S., Wyde P., Du R.-P., Snell E., Yan W.-Y., Wang Q., Gisonni L., Sanhueza S., Ewasysshyn M. and Klein M., *Virus Genes* 14, 65-74, 1997
- 5 14. Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, J.W., Minamitani, M. and Meiklejohn, G. (1969) *Am. J. Epidemiol.* 89 (4), 435-448.
- 10 15. Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. (1969) *Am. J. Epidemiol.* 89 (4), 449-463.
- 15 16. Jensen, K.E., Peeler, B.E. and Dulworth, W.G. (1962) *J. Immunol.* 89, 216-226.
17. Murphy, B.R., Prince, G.A., Collins, P.L., Van Wyke-Coelingh, K., Olmsted, R.A., Spriggs, M.K., Parrott, R.H., Kim, H.-Y., Brandt, C.D. and Chanock, R.M. (1988) *Vir. Res.* 11, 1-15.
- 20 18. Hall, S.L., Sarris, C.M., Tierney, E.L., London, W.T., and Murphy, B.R. (1993) *J. Infect. Dis.* 167, 958-962.
- 25 19. Belshe, R.B., Karron, R.A., Newman, F.K., Anderson, E.L., Nugent, S.L., Steinhoff, M., Clements, M.L., Wilson, M.H., Hall, S.L., Tierney, E.L. and Murphy, B.R. (1992) *J. Clin. Microbiol.* 30 (8), 2064-2070.
- 30 20. Hall, S.L., Stokes, A., Tierney, E.L., London, W.T., Belshe, R.B., Newman, F.C. and Murphy, B.R. (1992) *Vir. Res.* 22, 173-184.
- 35 21. Van Wyke Coelingh, K.L., Winter, C.C., Tierney, E.L., London, W.T. and Murphy, B.R. (1988) *J. Infect. Dis.* 157 (4), 655-662.
- 40 22. Ray, R., Novak, M., Duncan, J.D., Matsuoka, Y. and Compans, R.W. (1993) *J. Infect. Dis.* 167, 752-755.
23. Ray, R., Brown, V.E. and Compans, R.W. (1985) *J. Infect. Dis.* 152 (6), 1219-1230.
- 45 24. Ray, R. and Compans, R.W. (1987) *J. Gen. Virol.* 68, 409-418.

25. Ray, R., Glaze, B.J., Moldoveanu, Z. and Compans, R.W. (1988) *J. Infect. Dis.* 157 (4), 648-654.
- 5 26. Ray, R., Matsuoka, Y., Burnett, T.L., Glaze, B.J. and Compans, R.W. (1990) *J. Infect. Dis.* 162, 746-749.
- 10 27. Ray, R., Glaze, B.J. and Compans, R.W. (1988) *J. Virol.* 62 (3), 783-787.
28. Ewasyshyn, M., Caplan, B., Bonneau A.-M., Scollard, N., Graham, S., Usman, S. and Klein, M. (1992) *Vaccine* 10 (6), 412-420.
- 15 29. Ambrose, M.W., Wyde, P.R., Ewasyshyn, M., Bonneau, A.-M., Caplan, B., Meyer, H.L. and Klein, M. (1991) *Vaccine* 9, 505-511.
- 20 30. Kasel, J.A., Frank, A.L., Keitel, W.H., Taber, L.H., Glezen W.P. *J. Virol.* 1984; 52:828-32.
31. Lehman, D.J., Roof, L.L., Brideau, R.J., Aeed, P.A., Thomsen, D.R., Elhammer, A.P., Wathen, M.W. and Homa, F.L. (1993) *J. Gen. Virol.* 74, 459-469.
- 25 32. Brideau, R.J., Oien, N.L., Lehman, D.J., Homa, F.L. and Wathen, M.W. (1993) *J. Gen. Virol.* 74, 471-477.
- 30 33. Ebata, S.N., Prevec, L., Graham, F.L. and Dimock, K. (1992) *Vir. Res.* 24, 21-33.
34. Hall, S.L., Murphy, B.R. and Van Wyke Coelingh, K.L. (1991) *Vaccine* 9, 659-667.
- 35 35. Strauss E.G. and Strauss J.H., in Schlesinger S.S. and Schlesinger M.i. (eds). *The Togaviridae and Flaviviridae*. Plenum Press, New York, 1986, pp.35-90.
- 40 36. Chapman, B.S.; Thayer, R.M.; Vincent, K.A. and Haigwood, N.L., *Nucl. Acids. Res.* 1991, 19: 3979-3986.
- 45 37. Breathnack, R. and Harris, B.A., *Nucl. Acids Res.* 1983, 11: 7119-7136

38. Nabel, G.J. 1993, Proc. Natl. Acad. Sci. USA 90:
11307-11311.
- 5 39. Tang et al., Nature 1992, 356: 152-154
40. Furth et al. Analytical Biochemistry, 1992, 205:
365-368
- 10 41. Prince, G.A. et al, Am. J. Pathol. 93, 771 to 790,
1978.

CLAIMS

What we claim is:

1. A vector, comprising:
 - 5 a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; and
 - a second DNA sequence encoding a paramyxovirus
 - 10 protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication, the first and second DNA sequences being
 - 15 under transcriptional control of a promoter.
2. The vector of claim 1 wherein the paramyxovirus protein is selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial
- 20 virus (RSV).
3. The vector of claim 2 wherein the PIV protein is selected from the group consisting of PIV-1, PIV-2, PIV-3 and PIV-4
- 25
4. The vector of claim 3 wherein said PIV protein is selected from the group consisting of the HN and F glycoproteins of PIV-3.

5. The vector of claim 4 wherein the RSV protein is selected from the group consisting of the F or G glycoprotein of RSV.
- 5 6. The vector of claim 1 wherein the second DNA sequence encodes a full length RSV F or RSV G proteins.
7. The vector of claim 1, wherein the second nucleotide sequence encodes a truncated RSV F or RSV G
10 protein lacking the transmembrane anchor and cytoplasmic tail.
8. The vector of claim 1 wherein the alphavirus is a Semliki Forest virus.
- 15 9. The vector of claim 1 wherein the first DNA sequence is the Semliki Forest viral sequence contained in plasmid pSFVI.
- 20 10. The vector of claim 1 wherein the promoter sequence is an immediate early cytomegalovirus (CMV) promoter.
11. The vector of claim 1 further comprising a third DNA sequence located adjacent the second DNA sequence
25 to enhance the immunoprotective ability of the paramyxovirus protein when expressed *in vivo* from the vector in a host.
12. The vector of claim 11 wherein the third nucleotide
30 sequence comprises a pair of splice sites to prevent aberrant mRNA splicing, *in vivo* whereby substantially

35

all transcribed mRNA from the vector region
administration encodes the RSV protein.

13. The vector of claim 12 wherein the third nucleotide
5 sequence is located between the first nucleotide
sequence and the promoter sequence.

14. The vector of claim 13 wherein said third
nucleotide sequence is that of rabbit β -globin intron
10 II.

15. The vector of claim 10 wherein said promoter
sequence is an immediate early cytomegalovirus (CMV)
promoter and the human cytomegalovirus Intron A
15 sequence is provided downstream of the promoter and
upstream of the third nucleotide sequence.

16. The vector of claim 15 further comprising a fourth
nucleotide sequence at the 3'-end of the first
20 nucleotide sequence to ensure proper *in vivo* cleavage
at the 3'-end of the first nucleotide sequence.

17. The vector of claim 16 wherein said fourth
nucleotide sequence is a hepatitis delta virus ribozyme
25 sequence.

18. The vector of claim 1 which has the identifying
characteristics of plasmid pMP44 shown in Figure 2D.

30 19. The vector of claim 1 which has SEQ ID No: 1.

36

20. A method of immunizing a host against disease caused by infection with paramyxovirus, which comprises administering to the host an effective amount of a vector as claimed in claim 1.

5

21. The method of claim 21 wherein said vector has the identifying characteristics of plasmid pMP44 shown in Figure 2D.

10 22. The method of claim 21 wherein said vector has SEQ ID no: 1.

23. A method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of
15 generating antibodies which specifically react with RSV F or G protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises:

isolating said gene;
20 operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-essential for replication
25 to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; and
introducing the vector into the host.

24. The method of claim 23 wherein said gene encoding
30 an RSV F protein encodes an RSV F protein lacking the transmembrane region.

25. The method of claim 24 wherein said promoter comprises the immediate early cytomegalovirus promoter.

5 26. The method of claim 25 including the step of:
operatively linking said gene to an immunoprotective enhancing sequence to produce an enhanced immunoprotection to said RSV F protein in said host.

10

27. The method of claim 26 wherein said immunoprotective enhancing sequence is introduced into said vector between said control sequence and said gene.

15 28. The method of claim 27 wherein said immunoprotection enhancing sequence comprises a pair of splice sites to prevent aberrant mRNA splicing whereby substantially intact transcribed mRNA encodes an RSV F protein.

20

29. The method of claim 28 wherein said immunoprotection enhancing sequence is that of rabbit β -globin intron II.

25 30. The method of claim 23 wherein said vector is plasmid pMP44.

31. The vector of claim 23 wherein said vector has SEQ ID no: 1.

30

38

32. A method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises:

isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent;

operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; and

formulating the vector as a vaccine for *in vivo* administration.

33. The composition of claim 32 wherein said vector has the identifying characteristics of pMP44 shown in Figure 2D.

34. The method of claim 32 wherein said vector has SEQ ID no: 1.

35. A vaccine for administration to a host, including a human host, produced by the method of claim 32.

36. An immunogenic composition comprising an immunoeffective amount of a vector of claim 1.

30

39

37. The composition of claim 36 wherein said vector has the identifying characteristic of pMP44 in Figure 2D.

38. The composition of claim 36 wherein said vector has

5 SEQ ID no: 1.

1/16

~~Figure 4~~ Construction of pMP44⁴¹




Fig. 4b 1a

2/16





Fig 1B

3/16



+ Bam HI fragments
from pMP37

↓
Ligate

↓

Fig 1c




FIG 10

5/16


Figure 1 Construction of pMP44

fig. 2A

6/16




Fig. 20

Figure 2 Nucleotide sequence of plasmid pMP44

```

tcgcgcgttt  cggtgatgac  ggtgaaaacc  tctgacacat  gcagctcccg  gagacgggtca  60
cagcttgtct  gtaagcggat  gccgggagca  gacaagcccg  tcagggcgcg  tcagcgggtg  120
ttggcgggtg  tcggggctgg  ctttaactatg  cggcatacaga  gcagattgta  ctgagagtgc  180
accatatgcg  gtgtgaaata  ccgcacagat  gcgtaaggag  aaaataccgc  atcagattgg  240
ctattggcca  ttgcatacgt  tgtatccata  tcataatatg  tacatttata  ttggctcatg  300
tccaacatta  ccgccatggt  gacattgatt  attgactagt  tattaatagt  aatcaattac  360
ggggtcatta  gttcatagcc  catatatgga  gttccgcgtt  acataactta  cggtaaatgg  420
cccgctggc  tgaccgcca  acgaccccg  ccattgacg  tcaataatga  cgtatgttcc  480
catagtaacg  ccaataggga  ctttcattg  acgtcaatgg  gtggagtatt  tacggtaaac  540
tgcccacttg  gcagtacatc  aagtgtatca  tatgccaaat  acgcccccta  ttgacgtcaa  600
tgacggtaaa  tggcccgcct  ggcattatgc  ccagtacatg  accttatggg  actttcctac  660
ttggcagtag  atctacgtat  tagtcacgc  tattaccatg  gtgtagcggt  ttggcagta  720
catcaatggg  cgtggatagc  ggtttgactc  acggggattt  ccaagtctcc  accccattga  780
cgtcaatggg  agtttgtttt  ggcacaaaa  tcaacgggac  tttccaaaat  gtcgtaacaa  840
ctccgcccc  ttgacgcaaa  tgggcggtag  gcgtgtacgg  tgggaggtct  atataagcag  900
agctcgttta  gtgaaccgct  agatcgctg  gagacggcat  ccacgtgtt  ttgacctcca  960
tagaagacac  cggaaccgat  ccagcctccg  cgcccgggaa  cggtgcattg  gaacgcggat  1020
tccccgtgcc  aagagtgcg  taagtaccgc  ctatagactc  tataggcaca  cccctttggc  1080
tctatgcat  gctatactgt  ttttggcttg  gggcctatac  acccccgctt  ccttatgcta  1140
tagtgatgg  tatagcttag  cctataggtg  tgggttattg  accattattg  accactcccc  1200
tattggtgac  gatactttcc  attactaatc  cataacatgg  ctctttgcca  caactatctc  1260
tattggctat  atgccaatac  tctgtccttc  agagactgac  acggactctg  tatttttaca  1320
ggatggggtc  ccatttatta  ttacaaaatt  cacatataca  acaacgccgt  ccccggtgcc  1380
cgcagttttt  attaaacata  gcgtgggatc  tccacgcgaa  tctcgggtac  gtgttccgga  1440
catgggctct  tctccggtag  cggcgagct  tccacatccg  agccctggtc  ccatgcctcc  1500
agcggctcat  ggtcgctcgg  cagctccttg  ctctaacag  tggaggccag  acttaggcac  1560
agcacaatgc  ccaccaccac  cagtgtgccg  cacaaggccg  tggcggtagg  gtatgtgtct  1620
gaaaatgagc  gtggagattg  ggctcgcacg  gctgacgcag  atggaagact  taaggcagcg  1680
gcagaagaag  atgcaggcag  ctgagttgtt  gtattctgat  aagagtcaga  ggtaactccc  1740
gttcggtgac  gttaacgggt  ggaggcagc  gtagtctgag  cagtactcgt  tgctgccgct  1800
cgccgccacca  gacataatag  ctgacagact  aacagactgt  tcctttccat  gggctctttc  1860
cgatcctgag  aactcaggg  tgagtttggg  gacccttgat  tgttctttct  ttttcgctat  1920
tgtaaaattc  atgttatatg  gagggggcaa  agttttcagg  gtgtgtttta  gaatgggaag  1980
atgtcccttg  tatcaccatg  gaccctcatg  ataattttgt  ttctttcact  ttctactctg  2040
ttgacaacca  ttgtctcctc  ttattttctt  ttcattttct  gtaacttttt  cgtaaacttt  2100
tagcttgcat  ttgtaacgaa  tttttaaatt  cacttttgtt  tatttgtcag  attgtaagta  2160
ctttctctaa  tcactttttt  ttcaaggcaa  tcagggtata  ttatattgta  cttcagcaca  2220
gttttagaga  acaattgtta  taattaaatg  ataaggtaga  atatttctgc  atataaattc  2280
tggctggcgt  ggaaatattc  ttattggtag  aaacaactac  atcctgggtc  tcactcctgc  2340
tttctctta  tggttacaat  gatatacact  gtttgagatg  aggataaaat  actctgagtc  2400
caaacggggc  ccctctgcta  accatgttca  tgccttcttc  tttttcctac  agctcctggg  2460
caacgtgctg  gttattgtgc  tgtctcatca  ttttggcaaa  gaattgtaat  acgactcact  2520
atagggcgaa  ttgtcaccgt  cgctcgacatg  gcggatgtgt  gacatacacg  acgcaaaaag  2580
attttgttcc  agctcctgcc  acctccgcta  cgcgagagat  taaccacca  cgatggccgc  2640
caaagtgcac  gttgatattg  aggctgacag  cccattcatc  aagtctttgc  agaaggcatt  2700
tccgtcgttc  gaggtggagt  cattgcaggt  cacaccaaat  gaccatgcaa  atgccagagc  2760
attttcgcac  ctggttacca  aattgatcga  gcaggagact  gacaaagaca  cactcatctt  2820
ggatatcggc  agtgcgcctt  ccaggagaat  gatgtctacg  cacaaatacc  actgcgtatg  2880
ccctatgcgc  agcgcagaag  acccgaaaag  gctcgatagc  tacgcaaga  aactggcagc  2940
ggcctccggg  aaggtgctgg  atagagagat  cgcgagaaa  atcaccgacc  tgcagaccgt  3000
catggctacg  ccagacgctg  aatctcctac  cttttgcctg  catacagacg  tcacgtgtcg  3060
tacggcagcc  gaagtggccg  tataccagga  cgtgtatgct  gtacatgcac  caacatcgct  3120
gtaccatcag  gcgatgaaag  gtgtcagaac  ggcgtattgg  attgggtttg  acaccacccc  3180
gtttatgttt  gacgcgctag  caggcgcgta  tccaacctac  gccacaaact  gggccgacga  3240

```



```

gcaggtgtta caggccagga acataggact gtgtgcagca tccttgactg aggggaagact 3300
cggaactctg tccattctcc gcaagaagca attgaaacct tgcgacacag tcatgttctc 3360
ggtaggatct acattgtaca ctgagagcag aaagctactg aggagctggc acttaccctc 3420
cgtattccac ctgaaaggta aacaatcctt tacctgtagg tgcgatacca tcgtatcatg 3480
tgaagggtac gtagttaaga aaatcactat gtgccccggc ctgtacggta aaacggtagg 3540
gtacgccgtg acgtatcacg cggagggatt cctagtgtgc aagaccacag acactgtcaa 3600
aggagaaaga gtctcattcc ctgtatgcac ctacgtcccc tcaaccatct gtgatcaa 3660
gactggcata ctagcgaccg acgtcacacc ggaggacgca cagaagttgt tagtgggatt 3720
gaatcagagg atagttgtga acggaagaac acagcgaaac actaacacga tgaagaacta 3780
tctgtctccg attgtggccg tcgcatttag caagtgggag agggaaatac aggcagacct 3840
tgatgatgaa aaacctctgg gtgtccgaga gaggtcactt acttgctgct gcttgtgggc 3900
atttaaacag aggaagatgc acaccatgta caagaacca gacccccaga caatagttaa 3960
ggtgccttca gagttaact cgttcgtcat cccgagccta tggctctacag gcctcgcaat 4020
cccagtcaga tcacgcatta agatgctttt ggccaagaag accaagcgag agttaatacc 4080
tgttctcgac gcgtcgtcag ccagggatgc tgaacaagag gagaaggaga ggttggaggc 4140
cgagctgact agagaagcct taccaccctc cgtccccatc gcgcccggcg agacgggagt 4200
cgtcgacgtc gacgttgaa gactagagta tcacgcaggt gcaggggtcg tggaaacacc 4260
tcgcagcgcg ttgaaagtca ccgcacagcc gaacgacgta ctactaggaa attacgtagt 4320
tctgtctccc cagaccgtgc tcaagagctc caagttggcc cccgtgcacc ctctagcaga 4380
gcaggtgaaa ataataacac ataacgggag ggccggcggt taccaggtcg acggatatga 4440
cggcaggggt ctactacat gtggatcggc cattccggtc cctgagtttc aagctttgag 4500
cgagagcgcc actatggtgt acaacgaaag ggagttcgtc aacaggaaac tataccatat 4560
tgccgttcac ggaccgtcgc tgaacaccga cgaggagaac tacgagaaag tcagagctga 4620
aagaactgac gccgagtac gtgtcgacgt agataaaaaa tgctgcgtca agagagagga 4680
agcgtcgggt ttggtgttgg tgggagagct aaccaacccc ccgttccatg aattcgctta 4740
cgaagggtctg aagatcaggc cgtcggcacc atataagact acagtagtag gagtctttgg 4800
ggttccggga tcaggcaagt ctgctattat taagagcctc gtgaccaaac acgatctggt 4860
caccagcgcc aagaaggaga actgcccagga aatagttaac gacgtgaaga agcaccgcgg 4920
gaaggggaca agtagggaaa acagtgactc catcctgcta aacgggtgtc gtcgtgccgt 4980
ggacatccta tatgtggacg aggttttcgc ttgccattcc ggtactctgc tggcccta 5040
tgctcttgtt aaacctcgga gcaagtggt gttatgcgga gaccccaagc aatgcggatt 5100
cttcaatgat atgcagctta agtgaaact caaccacaac atctgcactg aagtatgta 5160
taaaagtata tccagacgtt gcacgcgtcc agtcacggcc atcgtgtcta cgttgacta 5220
cggaggcaag atgcgcacga ccaaccctg caacaaaccc ataatacatg acaccacag 5280
acagaccaag cccaagccag gagacatcgt gttaacatgc ttccgaggct gggcaagca 5340
gctgcagttg gactaccgtg gacacgaagt catgacagca gcagcatctc agggcctgc 5400
ccgcaaaagg gtatacgccg taaggcagaa ggtgaatgaa aatcccttgt atgccctgc 5460
gtcggagcac gtgaatgtac tgctgacgcy cactgaggat aggtgtgtgt ggaacacgt 5520
ggccggcgat ccctggatta aggtcctatc aaacattcca cagggttaact ttacggccac 5580
attggaagaa tggcaagaag aacacgacaa aataatgaag gtgattgaag gaccggctgc 5640
gcctgtggac gcgttcaga acaaaagcga cgtgtgttgg gcgaaaagcc tgggtgcctgt 5700
cctggacact gccggaatca gattgacagc agaggagtgg agcaccataa ttacagcatt 5760
taaggaggac agagcttact ctccagtggg ggccttgaat gaaatttgca ccaagtacta 5820
tggagtgtac ctggacagtg gcctgttttc tgcccgaag gtgtccctgt attacgagaa 5880
caaccactgg gataacagac ctggtggaag gatgtatgga ttcaatgccg caacagctgc 5940
caggctggaa gctagacata ccttcctgaa ggggcagtgg catacgggca agcaggcagt 6000
tatcgagaa agaaaaatcc aaccgcttcc tgtgctggac aatgtaattc ctatcaaccg 6060
caggctgccg cacgccctgg tggctgagta caagacggtt aaaggcagta gggttgagt 6120
gctggatcaat aaagtaagag ggtaccacgt cctgctgggt agtgagtaca acctggcttt 6180
gcctcgacgc agggctcactt ggttgcacc gctgaatgtc acaggcgccg ataggtgcta 6240
cgacctaaat ttaggactgc cggctgacgc cggcagggtc gacttggctt ttgtgaacat 6300
tcacacggaa ttcagaatcc accactacca gcagtgtgtc gaccacgcca tgaagctgca 6360
gatgcttggg ggagatgcgc tacgactgct aaaacccggc ggcattctga tgagagctta 6420
cggatagccc gataaaatca gcgaagccgt tgtttcctcc ttaagcagaa agttctcgtc 6480
tgcaagagtg ttgcgcccgg attgtgtcac cagcaataca gaagtgttct tgctgttctc 6540
caactttgac aacggaaaga gacctctac gctacaccag atgaatacca agctgagctc 6600
cgtgtatgcc ggagaagcca tgcacacggc cgggtgtgca ccatcctaca gagttaagag 6660

```

```

agcagacata gccacgtgca cagaagcggc tgtggttaac gcagctaack cccgtggaac 6720
tgtaggggat ggcgtatgca gggccgtggc gaagaaatgg ccgtcagcct ttaagggagc 6780
agcaacacca gtgggcacaa ttaaaacagt catgtgcggc tcgtaccccg tcatccacgc 6840
tgtagcgccct aatttctctg ccacgactga agcgggaagg gaccgcgaat tggccgctgt 6900
ctaccgggca gtggccgcgc aagtaaacag actgtcactg agcagcgtag ccatcccgct 6960
gctgtccaca ggagtgttca gcggcggaag agataggctg cagcaatccc tcaaccatct 7020
attcacagca atggacgcca cggacgctga cgtgaccatc tactgcagag acaaaagtgt 7080
ggagaagaaa atccaggaag ccattgacat gaggacggct gtggagtgtc tcaatgatga 7140
cgtggagctg accacagact tgggtgagagt gcacccggac agcagcctgg tgggtcgtaa 7200
gggtacagt accactgacg ggtcgctgta ctctactttt gaaggtacga aattcaacca 7260
ggctgctatt gatattggcag agatactgac gttgtggccc agactgcaag aggcaaacga 7320
acagatatgc ctatacgcgc tgggcaaac aatggacaac atcagatcca aatgtccggt 7380
gaacgattcc gattcatcaa cacctcccag gacagtggcc tgcctgtgcc gctacgcaat 7440
gacagcagaa cggatcgccc gccttaggtc acaccaagtt aaaagcatgg tggtttgctc 7500
atcttttccc ctcccgaaat accatgtaga tggggtgcag aaggtaaagt gcgagaaggt 7560
tctcctgttc gaccgcgagg taccttcagt ggttagtccg cgggaagtatg ccgcatctac 7620
gacggaccac tcagatcggt cgttacgagg gtttgacttg gactggacca ccgactcgctc 7680
ttccactgcc agcgatacca tgtcgctacc cagtttgtag tctgttgaca tgcactcgat 7740
ctacgagcca atggctccca tagtagtgac ggctgacgta caccctgaac ccgacggcat 7800
cgcgacactg gcggcagatg tgcacctga accgcagac catgtggacc tcgagaacct 7860
gattcctcca ccgcgcccga agagagctgc atacctggcc tcccgcgcg cggagcgacc 7920
ggtgccggcg ccgagaaagc cgacgcctgc ccaaggact gcgttttaga acaagctgcc 7980
tttgacgttc ggcgactttg acgagcacga ggtcgatgct ttggcctccg ggattacttt 8040
cggagacttc gacgacgtcc tgcgactagg ccgcgcgggt gcatatattt tctcctcgga 8100
cactggcagc ggacatttac acaaaaaatc cgttaggcag cacaatctcc agtgcgcaca 8160
actggatgcg gtccaggagg agaaaaatgta cccgccaaaa ttggatactg agaggagaaa 8220
gctgttgctg ctgaaaatgc agatgcaccc atcggaggct aataagagtc gataccagtc 8280
tcgcaaagtg gagaacatga aagccacggt ggtggacagg ctacacatcg gggccagatt 8340
gtacacggga gcggcagtag gccgcatacc aacatacgcg gttcggtagc cccgccccgt 8400
gtactccctt accgtgatcg aaagattctc aagccccgat gtagcaatcg cagcgtgcaa 8460
cgaataccta tccagaaatt acccaacagt ggcgtcgtag cagataacag atgaatacga 8520
cgcatacttg gacatggttg acgggtcgga tagttgcttg gacagagcga cattctgccc 8580
ggcgagctc cggtgctacc cgaaaacatca tgcgtaccac cagccgactg tacgcagtgc 8640
cgtcccgta ccctttcaga acacactaca gaacgtgcta gcggccgcca ccaagagaaa 8700
ctgcaacgtc acgcaaatgc gagaactacc caccatggag tcggcagtggt tcaacgtgga 8760
gtgcttcaag cgctatgcct gctccggaga atattgggaa gaatatgcta acaacctat 8820
ccggataacc actgagaaca tccactaccta tgtgacaaa ttgaaaggcc cgaagctgc 8880
tgccttggtc gctaagacct acaacttggt tccgctgcag gaggttccca tggacagatt 8940
cacggtcgac atgaaacgag atgtcaaagt cactccaggg acgaaacaca cagaggaaa 9000
acccaaagtc caggtaattc aagcagcgga gccattggcg accgcttacc tgtgcggcat 9060
ccacagggaa ttagtaagga gactaaatgc tgtgttacgc cctaacgtgc acacattggt 9120
tgatatgtcg gccgaagact ttgacgcgat catcgccctc cacttccacc caggagacct 9180
ggttctagag accgacattg catcattcga caaaagccag gacgactcct tggctcttac 9240
aggtttaatg atcctcgaag atctagggtt ggatcagtac ctgctggact tgatcgaggc 9300
agcctttggg gaaatatcca cgtgtcacct accaactggc acgcgcttca agttcgagc 9360
tatgatgaaa tcgggcatgt ttctgacttt gtttattaac actgttttga acatcaccat 9420
agcaagcagg gtactggagc agagactcac tgactccgcc tgtgcggcct tcatcggcga 9480
cgacaacatc gttcacggag tgatctccga caagctgatg gcggagaggt gcgcgtcgtg 9540
ggtcaacatg gaggtgaaga tcattgacgc tgtcatgggc gaaaaacccc catatttttg 9600
tgggggatcc atagtttttg acagcgtcac acagaccgcc tgcctgtttt cagaccact 9660
taagcgccgt ttcaagtggg gtaagccgct aacagctgaa gacaagcagg acgaagacag 9720
gcgacgagca ctgagtgcag aggttagcaa gtggttccgg acaggcttgg gggccgaact 9780
ggaggtggca ctaacatcta ggtatgaggt agagggctgc aaaagtatcc tcatagccat 9840
ggccaccttg gcgagggaca ttaaggcgtt taagaaattg agaggacctg ttatacacct 9900
ctacggcggt cctagattgg tgcgttaata cacagaattc tgattggatc atagcgact 9960
attataggat ccgcgcgcgc gaattcggca cgagtaacaa tggagtgtct aatcctcaa 10020
gcaaatgcaa ttaccacaat cctcactgca gtcacatttt gttttgcttc tggcctaaa 10080

```

10/16

atcactgaag	aattttatca	atcaacatgc	agtgcaagta	gcaaaggcta	tcttagtgct	10140
ctgagaactg	gttggtatac	cagtggtata	actatagaat	taagtaatat	caaggaaaaat	10200
aagtgtaatg	gaacagatgc	taaggtaaaa	ttgataaaac	aagaattaga	taaatataaa	10260
aatgctgtaa	cagaattgca	gttgctcatg	caaaacacac	cagcagcaaa	caatcgagcc	10320
agaagagaac	taccaagggt	tatgaattat	acactcaaca	atgccaaaaa	aaccaatgta	10380
acattaagca	agaaaaaggaa	aagaagattt	cttggttttt	tgttagggtg	tggatctgca	10440
atcgccagtg	gcgttgctgt	atctaaggtc	ctgcacctag	aagggggaagt	gaacaagatc	10500
aaaagtgtc	tactatccac	aaacaaggct	gtagtcagct	tatcaaattg	agttagtgtc	10560
ttaaaccagca	aagtgttaga	cctcaaaaac	tatatagata	aacaattggt	acctattgtg	10620
aacaagcaaa	gctgcagcat	atcaaatata	gaaactgtga	tagagttcca	acaaaagaac	10680
aacagactac	tagagattac	cagggaattt	agtgtaaatg	cagggtgaac	tacacctgta	10740
agcacttaca	tgtaactaa	tagtgaatta	ttgtcattaa	tcaatgat	gcctataaca	10800
aatgatcaga	aaaagttaat	gtccaacaat	gttcaaatag	ttagacagca	aagttactct	10860
atcatgtcca	taataaaaga	ggaagtctta	gcatatgtag	tacaattacc	actatatggt	10920
gttatagata	cacctgttg	gaaactacac	acatccctc	tatgtacaac	caacacaaaa	10980
gaagggtcca	acatctgttt	aacaagaact	gacagaggat	ggtactgtga	caatgcagga	11040
tcagtatctt	tcttcccaca	agctgaaaca	tgtaaaagtc	aatcaaatcg	agtattttgt	11100
gacacaatga	acagttaaac	attaccaagt	gaaataaatc	tctgcaatgt	tgacatatct	11160
aaacccaaat	atgattgtaa	aattatgact	tcaaaaacag	atgtaagcag	ctccgttatc	11220
acatctctag	gagccattgt	gtcatgtctat	ggcaaaacta	aatgtacagc	atccaataaa	11280
aatcgtggaa	tcataaagac	attttctaac	gggtgcgatt	atgtatcaaa	taaagggatg	11340
gacactgtgt	ctgtaggtaa	cacattatat	tatgtaaaata	agcaagaagg	taaaagtctc	11400
tatgtaaaag	gtgaaccaat	aataaaattc	tatgacccat	tagtattccc	ctctgatgaa	11460
tttgatgcat	caatatctca	agtcaacgag	aagattaacc	agagcctagc	atttattcgt	11520
aatccgatg	aattattaca	taatgtaaat	gctggtaaat	ccaccacaaa	tatcatgact	11580
tgataatgag	gatccagatc	ccgggtaatt	aattgaatta	catccctacg	caaacgtttt	11640
acggcccgctg	gtggcgcccg	cgcccgcccg	cccgctcttg	gccgttgca	gccactccgg	11700
tggtccccgt	cgcccccgac	ttccaggccc	agcagatgca	gcaactcatc	agcgccgtaa	11760
atgcgctgac	aatgagacag	aacgcaattg	ctcctgctag	gcctcccaaa	ccaaagaaga	11820
agaagacaac	caaaccaaaag	ccgaaaaacgc	agcccaagaa	gatcaacgga	aaaacgcagc	11880
agcaaaagaa	gaaagacaag	caagccgaca	agaagaagaa	gaaacccgga	aaaagagaaa	11940
gaatgtgcat	gaagattgaa	aatgactgta	tcttcgtatg	cggctagcca	cagtaacgta	12000
gtgtttccag	acatgtcggg	caccgcacta	tcattgggtg	agaaaatctc	gggtggtctg	12060
ggggccttcg	caatcgccgc	tatcctggtg	ctggttgtgg	tcacttgcat	tgggtcccg	12120
agataagtta	gggtaggcaa	tggcattgat	atagcaagaa	aattgaaaac	agaaaaagtt	12180
agggtaaagca	atggcatata	accataactg	tataacttgt	aacaaagcgc	aacaagacct	12240
gcgcaattgg	cccggtgggc	cgccctacgg	aaactcgggg	caactcatat	tgacacatta	12300
attggcaata	attggaagct	tacataagct	taattcgacg	aataattgga	tttttatttt	12360
attttgcaat	tggttttttaa	tatttccaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	12420
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	gagggtcggc	atggcatctc	12480
cacctcctcg	cggtccgacc	tgggcatccg	aaggaggacg	cacgtccact	cggtgggta	12540
agggagagat	ccagatctgc	tgtgccttct	agttgccagc	catctgttgt	ttgcccctcc	12600
cccgtgcctt	ccttgaccct	ggaaggtgcc	actcccactg	tcctttccta	ataaaatgag	12660
gaaattgcat	cgcattgtct	gagtaggtgt	cattctattc	tgggggggtg	ggtggggcag	12720
gacagcaagg	gggaggattg	ggaagacaat	agcaggcatg	ctggggatgc	ggtgggctct	12780
atgggtaccg	aggtgctgaa	gaattgaccc	ggttcctcct	gggccagaaa	gaagcaggca	12840
catcccttcc	tctgtgacac	accctgtcca	cgccctgggt	tcttagttcc	agccccactc	12900
ataggacact	catagctcag	gagggtcccg	ccttcaatcc	caccgcctaa	agtacttgga	12960
gcggtctctc	cctccctcat	cagcccacca	aaccaaactc	agcctccaag	agtgggaaga	13020
aattaaagca	agataggcta	ttaagtgcag	agggagagaa	aatgcctcca	acatgtgagg	13080
aagtaatgag	agaaatcata	gaatttcttc	cgcttcctcg	ctcactgact	cgctgcgctc	13140
ggtcgttcgg	ctgcggcgag	cggtatcagc	tactcaaaag	gcggtataac	ggttatccac	13200
agaatcaggg	gataacgcag	gaaagaacat	gtgagcaaaa	ggccagcaaa	aggccaggaa	13260
ccgtaaaaag	gccgcgttgc	tggcgttttt	ccataggctc	cgcccccctg	acgagcatca	13320
caaaaatcga	cgctcaagtc	agaggtggcg	aaacccgaca	ggactataaa	gataccaggc	13380
gtttccccc	ggaagctccc	tctgtcgttc	tctgttccg	accctgccgc	ttaccggata	13440
cctgtccgcc	tttctccctt	cggaagcgt	ggcgtttct	catagctcac	gctgtaggta	13500

Fig 20

```

tttcagttcg gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac cccccgttca 13560
gccccgaccgc tgcgccttat ccggttaacta tcgtcttgag tccaacccgg taagacacga 13620
cttatcgcca ctggcagcag ccactggtaa caggatttagc agagcgaggt atgtaggcgg 13680
tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagaa cagtatttgg 13740
tatctgcgt ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg 13800
caaacaaacc accgctggta gcggtgggtt ttttgtttgc aagcagcaga ttacgcgcag 13860
aaaaaaagga tctcaagaag atcctttgat cttttctacg gggctctgacg ctcagtggaa 13920
cgaaaactca cgttaaggga ttttggctat gagattatca aaaaggatct tcacctagat 13980
ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc 14040
tgacagttac caatgcttaa tcagtgggc acctatctca gcgatctgtc tatttcgttc 14100
atccatagtt gcctgactcg gggggggggg gcgctgaggt ctgcctcgtg aagaaggtgt 14160
tgctgactca taccaggcct gaatcgcccc atcatccagc cagaaagtga gggagccacg 14220
gttgatgaga gctttgttgt aggtggacca gttggtgatt ttgactttt gctttgccac 14280
ggaacggtct gcgttgctcg gaagatgcgt gatctgatcc ttcaactcag caaaagttcg 14340
atatttcaa caaagccgcc gtcccgtcaa gtcagcgtaa tgctctgcca gtgttacaac 14400
caattaacca attgtgatta gaaaaactca tcgagcatca aatgaaactg caatttattc 14460
atatcaggat tatcaatacc atatttttga aaaagccgtt tctgtaatga aggagaaaac 14520
tcaccgaggc agttccatag gatggcaaga tcctggatc ggtctgcgat tccgactcgt 14580
ccaacatcaa tacaacctat taatttcccc tcgtcaaaaa taaggttatc aagtgagaaa 14640
tcaccatgag tgacgactga atccggtgag aatggcaaaa gcttatgcat ttctttccag 14700
acttgttcaa caggccagcc attacgctcg tcatcaaaat cactcgcac aaccaaaccg 14760
ttattcattc gtgattgcgc ctgagcgaga cgaaatacgc gatcgctgtt aaaaggacaa 14820
ttacaacag gaatcgaatg caaccggcgc aggaacactg ccagcgcac aacaatattt 14880
tcacctgaat caggatatte ttctaatacc tggaatgctg ttttcccggg gatcgagtg 14940
gtgagtaacc atgcatcatc aggagtacgg ataaaatgct tgatggctcg aagaggcata 15000
aattccgtca gccagtttag tctgaccatc tcatctgtaa catcattggc aacgctacct 15060
ttgccatgtt tcagaaacaa ctctggcgca tcgggcttcc catacaatcg atagattgtc 15120
gcacctgatt gcccgacatt atcgcgagcc catttatacc catataaatc agcatccatg 15180
ttggaattta atcgcgccct cgagcaagac gtttcccgtt gaatatggct cataacgttc 15240
cttgatttac tgtttatgta agcagacagt tttattgttc atgatgat atttttatct 15300
tgtgcaatgt aacatcagag attttgagac acaacgtggc tttccccccc cccccattat 15360
tgaagcattt atcagggtta ttgtctcatg agcggataca tatttgaatg tatttagaaa 15420
aataaaca aa taggggttcc gcgcacattt cccgaaaaag tgccacctga cgtctaagaa 15480
accattatta tcatgacatt aacctataaa aataggcgta tcacgaggcc ctttcgtc 15538

```

12/16

Figure 4. Anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after boosting




Figure 6ASFV Eco RV-Spe I fragment ligated to ribozyme

	atcggcagtg	cgccttccag	gagaatgatg	tctacgcaca	aataccactg	cgtatgccct	60
	atgcgcagcg	cagaagaccc	cgaaaggctc	gatagctacg	caaagaaact	ggcagcggcc	120
	tccgggaagg	tgctggatag	agagatcgca	ggaaaaatca	ccgacctgca	gacctgcatg	180
5	gctacgccag	acgctgaatc	tcctaccttt	tgctgcata	cagacgtcac	gtgtcgtacg	240
	gcagccgaag	tggccgtata	ccaggacgtg	tatgctgtac	atgcaccaac	atcgctgtac	300
	catcagggca	tgaagggtgt	cagaacggcg	tattggattg	ggtttgacac	caccccgttt	360
	atgtttgacg	cgctagcagg	cgctatcca	acctacgcca	caaactgggc	cgacgagcag	420
	gtgttacagg	ccaggaacat	aggactgtgt	gcagcatcct	tgactgaggg	aagactcggc	480
10	aaactgtcca	ttctccgcaa	gaagcaattg	aaaccttgcy	acacagtcac	gttctcggta	540
	ggatctacat	tgtacactga	gagcagaaag	ctactgagga	gctggcactt	acctccgta	600
	ttccacctga	aaggtaaaaca	atcctttacc	tgtagggtcg	ataccatcgt	atcatgtgaa	660
	gggtacgtag	ttaagaaaat	cactatgtgc	cccggcctgt	acggtaaaac	ggtagggtag	720
	gccgtgacgt	atcacgcgga	gggatttcta	gtgtgcaga	ccacagacac	tgtcaaagga	780
15	gaaagagctc	cattccctgt	atgcacctac	gtccctcaa	ccatctgtga	tcaaatgact	840
	ggcatactag	cgaccgacgt	cacacgggag	gacgcacaga	agttgttagt	gggattgaa	900
	cagaggatag	tgtgaacg	aagaacacag	cgaaacacta	acacgatgaa	gaactatctg	960
	cttccgattg	tggccgtcgc	atttagcaag	tgggagaggg	aatacaaggc	agaccttgat	1020
	gatgaaaac	ctctgggtgt	ccgagagagg	tcacttactt	gctgctgctt	gtgggcattt	1080
20	aaaacgagga	agatgcacac	catgtacaag	aaaccagaca	cccagacaat	agtgaagggt	1140
	ccttcagagt	ttaaactcgt	cgctcatccg	agcctatggt	ctacaggcct	cgcaatccca	1200
	gtcagatcac	gcattaagat	gcttttggcc	aagaagacca	agcgagagtt	aatacctggt	1260
	ctcgacgcgt	cgtcagccag	ggatgctgaa	caagaggaga	aggagaggtt	ggaggccgag	1320
	ctgactagag	aagccttacc	accctctgtc	cccctcgccg	cggcggagac	gggagtcgtc	1380
25	gacgtcgacg	ttgaagaact	agagtatcac	gcaggtgcag	gggtcgtgga	aacacctcgc	1440
	agcgcgttga	aagtcaccgc	acagccgaac	gacgtactac	taggaaatta	cgtagtcttg	1500
	tcccgcgaga	cgtgctcaa	gagctccaag	ttggccccc	tgcacctctc	agcagagcag	1560
	gtgaaaataa	taacacataa	cgggagggcc	ggcgttacc	aggtcgacgg	atatgacggc	1620
	aggtctctac	taccatgtgg	atcggccatt	ccggtccctg	agtttcaagc	tttgagcgag	1680
30	agcgccacta	tgggtgtaca	cgaaagggag	ttcgtcaaca	ggaaactata	ccatattgcc	1740
	gttcacggac	cgtogctgaa	caccgacgag	gagaactacg	agaaagtcag	agctgaaaga	1800
	actgacgccg	agtacgtgtt	cgacgtagat	aaaaaatgct	gcgtcaagag	agaggaagcg	1860
	togggtttgg	tgttgggtgg	agagctaacc	aacccccctg	tccatgaatt	cgcctacgaa	1920
	gggctgaaga	tcaggccgtc	ggcaccatat	aagactacag	tagtaggagt	ctttgggggt	1980
35	ccgggatcag	gcaagtctgc	tattattaag	agcctcgtga	ccaaacacga	tctggtcacc	2040
	agcggcaaga	aggagaactg	ccaggaaata	gttaacgacg	tgaagaagca	ccgcgggaag	2100
	gggacaagta	gggaaaacag	tgactccatc	ctgctaacy	gggtgcgtcg	tgccgtggac	2160
	atcctatatg	tggacgagcg	tttcgcttgc	cattccggta	ctctgctggc	ccatattgct	2220
	cttgttaaac	ctcggagcaa	agtgggtgta	tgccgagacc	ccaagcaatg	cggattcttc	2280
40	aatatgatgc	agcttaagg	gaacttcaac	cacaacatct	gcactgaagt	atgtcataaa	2340
	agtatatcca	gacgttgac	gcgtccagtc	acggccatcg	tgtctacgtt	gcactacgga	2400
	ggcaagatgc	gcacgaccac	ccggtgcaac	aaaccataa	tcatagacac	cacaggacag	2460
	accaagccca	agccaggaga	catcgtgtta	acatgcttcc	gaggtctggc	aaagcagctg	2520
	cagttggact	accgtggaca	cgaagtcacg	acagcagcag	catctcaggg	cctcaccgcg	2580
45	aaaggggtat	acgccgtaac	gcagaagggtg	aatgaaaatc	ccttgctatg	ccctgctcgc	2640
	gagcacgtga	atgtactgct	gacgcgcact	gaggataggg	tgggtgtgga	aacgctggcc	2700
	ggcgatccct	ggattaaagg	cctatcaaac	attccacagg	gtaactttac	ggccacattg	2760
	gaagaatggc	aagaagaaca	cgacaaaata	atgaagggtga	ttgaaggacc	ggctgcgcct	2820
	gtggacgcgt	tccagaacaa	agcgaacgtg	tgttggggca	aaagcctggt	gcctgtcctg	2880
50	gacactgccg	gaatcagatt	gacagcagag	gagtgagaca	ccataattac	agcatttaag	2940
	gaggacagag	cttactctcc	agtgggtggc	ttgaatgaaa	tttgacacaa	gtactatgga	3000
	gttgacctgg	acagtggcct	gttttctgcc	ccgaagggtg	cctgtatta	cgagaacaa	3060
	cactgggata	acagacctgg	tgggaaggatg	tatggattca	atgccgcaac	agctgccagg	3120
	ctggaagcta	gacatacctt	cctgaagggg	cagtggcata	cgggcaagca	ggcagttatc	3180
55	gcagaaaagaa	aaatccaacc	gctttctgtg	ctggacaatg	taattcctat	caaccgcagg	3240
	ctgccgcacg	ccctgggtgg	tgagtacaag	acggttaaag	gcagtagggg	tgagtggctg	3300
	gtcaataaag	taagagggta	ccacgtcctg	ctgggtgagt	agtacaacct	ggctttgctt	3360
	cgacgcaggg	tcacttggtt	gtcacccgtg	aatgtcacag	gcgcgcatag	gtgctacgac	3420

Ac. 66

	ctaagtttag	gactgccggc	tgacgccggc	aggttcgact	tgggtctttgt	gaacattcac	3480
	acggaattca	gaatccacca	ctaccagcag	tgtgtcgacc	acgccatgaa	gctgcagatg	3540
	cttgggggag	atgcgctacg	actgctaaaa	cccggcggca	tcttgatgag	agcttacgga	3600
	tacgccgata	aaatcagcga	agcggttgtt	tcctccctaa	gcagaaagt	ctcgtctgca	3660
5	agagtgttgc	gcccggattg	tgtcaccagc	aatacagaag	tgttcttgc	gttctccaac	3720
	tttgacaacg	gaaagagacc	ctctacgcta	caccagatga	ataccaagct	gagtgcctgt	3780
	tatgccggag	aagccatgca	cacggccggg	tgtgcacccat	cctacagagt	taagagagca	3840
	gacatagcca	cgtgcacaga	agcggctgtg	gttaacgcag	ctaacgccc	tggaaactgt	3900
	ggggatggcg	tatgcaggcg	cgtggcggaag	aaatggccgt	cagcccttaa	gggagcagca	3960
10	acaccagtgg	gcacaattaa	aacagtcacg	tgcggctcgt	accccgctcat	ccacgctgt	4020
	gcgcctaatt	tctctgcac	gactgaagcg	gaaggggacc	gcgaattggc	cgtgtcttac	4080
	cgggcagtgg	ccgcggaagt	aaacagactg	tactgagca	gcgtagccat	cccgtgtgt	4140
	tccacaggag	tgttcagcgg	cggaaagagat	aggctgcagc	aatccctcaa	ccatctattc	4200
	acagcaaatgg	acgccacgga	cgctgacgtg	accatctact	gcagagacaa	aagtggggag	4260
15	aagaaaatcc	aggaagccat	tgacatgagg	acggctgtgg	agttgctcaa	tgatgacgtg	4320
	gagctgacca	cagacttggg	gagagtgcac	ccggacagca	gcctgggtggg	tcgtaagggc	4380
	tacagtacca	ctgacgggtc	gctgtactcg	tactttgaag	gtacgaaatt	caaccaggtc	4440
	gctattgata	tggcagagat	aotgacgttg	tggcccagac	tgcaagaggc	aaacgaacag	4500
	atatgcctat	acgcgctggg	cgaaacaatg	gacaacatca	gatccaaatg	tccgggtgaa	4560
20	gattccyact	catcaacacc	tcccaggaca	gtgccctgcc	tgtgcgcta	cgcaatgaca	4620
	gcagaacgga	tcgcccgcct	taggtcacac	caagttaaaa	gcatgggtgg	ttgctcatct	4680
	tttccctccc	cgaaatacca	tgtagatggg	gtgcagaagg	taaagtgcga	gaaggttctc	4740
	ctgttcgacc	cgacggtacc	ttcagtggtt	agtccgcgga	agtatgcgc	atctacgacg	4800
	gaccactcag	atcggctcgt	acgaggggtt	gacttggact	ggaccacoga	ctcgtcttcc	4860
25	actgccagcg	ataccatgtc	gctaccaggt	ttgcagtcgt	gtgacatoga	ctcgatctac	4920
	gagccaatgg	ctcccatagt	agtgcagcgt	gacgtacacc	ctgaacccgc	agggcatcgc	4980
	gacctggcgg	cagatgtgca	ccctgaaccc	gcagaccatg	tggacctoga	gaacccgatt	5040
	cctccaccgc	gcccgaagag	agctgcatac	cttgccctccc	gcgcggcgga	gcgaccggtg	5100
	ccggcgccga	gaaagccgac	gcctgcccga	aggactgcgt	ttaggaacaa	gctgcctttg	5160
30	acgttcggcg	actttgacga	gcacgaggtc	gatgcgttgg	cctccgggat	tactttcoga	5220
	gacttcgacg	acgtcctgcg	actaggccgc	gcgggtgcat	atatcttctc	ctcggacact	5280
	ggcagcggac	atttacaaca	aaaatccggt	aggcagcaca	atctccagtg	cgcacaactg	5340
	gatgcgggtc	aggagygaga	aatgtaccgg	ccaaaattgg	atactgagag	ggagaagctg	5400
	ttgtcgtctg	aaatgcagat	gcacccatcg	gaggctaata	agagtcgata	ccagtctcgc	5460
35	aaagtggaga	acatgaaagc	cacggtygtg	gacaggctca	catcgggggc	cagattgtac	5520
	acgggagcgg	acgtaggccg	cataccaaca	tacgcggttc	ggtacccccg	ccccgtgtac	5580
	tcccctaccg	tgatcgaaag	attctcaagc	cccgatgtag	caatcgagc	gtgcaacgaa	5640
	tacctatcca	gaaattacc	aacagtggtg	tcgtaccaga	taacagatga	atacgacgca	5700
	tacttggaca	tggttgacgg	gtcggatagt	tgcttggaca	gagcgacatt	ctgcccggcg	5760
40	aagctccggg	gctacccgaa	acatcatgcg	taccaccagc	cgactgtacg	cagtgcctgc	5820
	ccgtcaccct	ttcagaacac	actacagaac	gtgctagcgg	ccgccacca	gagaaactgc	5880
	aacgtcacgc	aaatgcgaga	actaccacc	atggactcgg	cagtgttcaa	cgtggagtgc	5940
	ttaagcgct	atgcctgtc	cggagaatat	tgggaagaat	atgctaaca	acctatccgg	6000
	ataaccactg	agaacatcac	tacctatgtg	accaaattga	aaggcccgaa	agctgtctgc	6060
45	ttgttcgcta	agaccacaa	cttggttccg	ctgcaggagg	ttcccatgga	cagattcacg	6120
	gtcgacatga	aacgagatgt	caaagtcact	ccaggagcga	aacacacaga	ggaaagaccc	6180
	aaagtccagg	taattcaagc	agcggagcca	ttggcgaccg	cttacctgtg	cggcatccac	6240
	agggaaattg	taaggagact	aaatgctgtg	ttacgcctca	acgtgcacac	attgtttgat	6300
	atgtcggcgg	aagactttga	cgcatcatc	gcctctcact	tccaccacag	agaccgggtt	6360
50	ctagagacgg	acattgcac	attcgacaaa	agccaggacg	actccttggc	tcttacagg	6420
	ttaatgatcc	tcgaagatct	aggggtggat	cagtacctgc	tggacttgat	cgaggcagcc	6480
	tttggggaaa	tatccagctg	tcacctacca	actggcacgc	gcttcaagtt	cggagctatg	6540
	atgaaatcgg	gcattgtttt	gactttgttt	attaacactg	ttttgaaat	caccatagca	6600
	agcaggggtac	tggagcagag	actcactgac	tccgcctgtg	cggccttcat	cggcgagcag	6660
55	aacatcggtc	acggagtgt	ctccgacaag	ctgatggcgg	agaggtgcgc	gtcgtgggtc	6720
	aacatggagg	tgaagatcat	tgacgctgtc	atgggcgaaa	aacccccata	tttttggggg	6780
	ggattcatag	tttttgacag	cgtcacacag	accgcctgcc	gtgtttcaga	cccacttaag	6840
	cgcctgttca	agttgggtaa	gccgctaaca	gctgaagaca	agcaggacga	agacaggcga	6900
	cgagcactga	gtgacgaggt	tagcaagtgg	ttccggacag	gcttgggggc	cgaactggag	6960

6460

gtggcactaa catctaggta tgaggtagag ggctgcaaaa gtatcctcat agccatggcc 7020
 accttggcga gggacattaa ggcgtttaag aaattgagag gacctgttat acacctctac 7080
 ggcggtccta gattggtgcy ttaatacaca gaattctgat tggatcatag cgcactatta 7140
 taggatccag atcccgggta attaattgaa ttacatccct acgcaaacgt tttacggccg 7200
 5 ccggtggcgc ccgcgcccgc cggcccgtcc ttggccgttg caggccactc cgggtggctcc 7260
 cgtcgtcccc gacttccagg ccagcagat gcagcaactc atcagcgccg taaatgcgct 7320
 gacaatgaga cagaacgcaa ttgctcctgc taggcctccc aaaccaaga agaagaagac 7380
 aaccaacca aagccgaaaa cgcagcccaa gaagatcaac ggaaaaacgc agcagcaaaa 7440
 gaagaagac aagcaagccg acaagaagaa gaagaacccc ggaaaaagag aaagaatgtg 7500
 10 catgaagatt gaaaatgact gtatcttcgt atgcggttag ccacagtaac gtagtgtttc 7560
 cagacatgtc gggcaccgca ctatcatggg tgcagaaaat ctggggtggc ctgggggccc 7620
 tcgcaatcgg cgctatcctg gtgctgggtg tggtcacttg cattgggctc cgcagataag 7680
 ttagggtagg caatggcatt gatatagcaa gaaaattgaa aacagaaaaa gttagggtaa 7740
 gcaatggcat ataaccataa ctgtataact tgtaacaaag cgcaacaaga cctgcgcant 7800
 15 tggcccctg gtccgcctca cggaaaactc gggcaactca tattgacaca ttaattggca 7860
 ataattggaa gcttacataa gcttaattcg acgaataatt ggaattttat tttattttgc 7920
 aattggtttt taatatttcc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 7980
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa ctagcgggtc ggcattggcat ctccacctcc 8040
 20 tcgcggtccg acctgggcat ccgaaggagg acgcacgtcc actcggatgg ctaagggaga 8100

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 98/01064

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 C12N15/45 C07K14/135 C07K14/115 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 40945 A (CONNAUGHT LAB ;LI XIAOMAO (CA); EWASYSHYN MARY E (CA); SAMBHARA SU) 19 December 1996 cited in the application see the whole document, especially page 6, lines 2-9; page 14, lines 15-21; and page 23, lines 18-23 ---	1-36
Y	WO 95 27044 A (BIOPTION AB ;LILJESTROEM PETER (SE); GAROFF HENRIK (SE)) 12 October 1995 cited in the application see the whole document, especially page 8, lines 12-22 ---	1-36
A	WO 96 17072 A (VIAGENE INC) 6 June 1996 see the whole document ---	1-36
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 April 1999

Date of mailing of the international search report

03/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

INTERNATIONAL SEARCH REPORT

Intor. onal Application No

PCT/CA 98/01064

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ZHOU X. ET AL.: "Self-replicating Semliki-Forest virus RNA as recombinant vaccine" VACCINE, vol. 12, no. 16, 1994, pages 1510-1514, XP002089524 cited in the application see the whole document ----	1-36
A	LILJESTROEM P. ET AL.: "A NEW GENERATION OF ANIMAL CELL EXPRESSION VECTORS BASED ON THE SEMLIKI FOREST VIRUS REPLICON" BIO/TECHNOLOGY, vol. 9, December 1991, pages 1356-1361, XP000616021 cited in the application see the whole document ----	1-36
E,L	WO 99 11808 A (CONNAUGHT LAB ;PARRINGTON MARK (CA)) 11 March 1999 cited in the application see the whole document -----	1-9,20, 23,24, 32,35,36

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 98/01064

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 20-30
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/01064

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9640945 A	19-12-1996	AU 695527 B	13-08-1998
		AU 6117696 A	30-12-1996
		CA 2223610 A	19-12-1996
		EP 0832253 A	01-04-1998
		US 5843913 A	01-12-1998
		US 5880104 A	09-03-1999
WO 9527044 A	12-10-1995	AU 699384 B	03-12-1998
		AU 2155795 A	23-10-1995
		CA 2184261 A	12-10-1995
		EP 0753053 A	15-01-1997
		FI 963860 A	27-09-1996
		JP 9511143 T	11-11-1997
WO 9617072 A	06-06-1996	AU 4594996 A	19-06-1996
		EP 0797679 A	01-10-1997
		US 5814482 A	29-09-1998
		US 5843723 A	01-12-1998
		US 5789245 A	04-08-1998
WO 9911808 A	11-03-1999	NONE	